Making therapies that make a difference

Our clinical and preclinical pipeline includes wholly-owned and partnered therapeutic candidates initially targeting cancers.

Pipeline of Potential

Lead Product Candidates

Preclinical
Phase 1
Phase 2
Pivotal
Commercial Rights

ZW25

HER2 x HER2 Bispecific Antibody

  • Azymetric™
Phase 2
BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
  • Biliary Tract Cancer
  • Breast Cancer
  • Gastroesophageal Adenocarcinomas
  • Other HER2-Expressing Cancers
Full Details
  • Biliary Tract Cancer
  • Gastroesophageal Adenocarcinomas
  • Breast Cancer
  • Other HER2-Expressing Cancers
  • Phase 1

    Single Agent & Chemotherapy Combination

    Now Enrolling Patients
  • Gastroesophageal Adenocarcinomas
  • Phase 2

    Chemotherapy Combination

    Now Enrolling Patients
  • Breast Cancer
  • Phase 2

    Combination with Palbociclib & Fulvestrant

    Now Enrolling Patients

    ZW49

    HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)

    • Azymetric™
    • ZymeLink™
    Phase 1
    BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
    • HER2-Expressing Cancers
    Full Details
  • Biliary Tract Cancer
  • Phase 1

    Single Agent

    Now Enrolling Patients

    Preclinical & Advanced Discovery

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    Antibody Drug Conjugate (ADC)

    • Azymetric™
    • ZymeLink™
    Preclinical
    • Solid Tumors
    Full Details

    T Cell Engaging Bispecifics

    • Azymetric™
    • EFECT™
    Preclinical
    • Solid Tumors
    Full Details

    Microenvironment Modulators

    • Azymetric™
    • EFECT™
    Preclinical
    • Solid Tumors
    Full Details

    Cytokine Receptor Modulators

    • Azymetric™
    • EFECT™
    Preclinical
    • Inflammation
    • Autoimmune
    Full Details

    Partnerships

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    Bispecific

    • Azymetric™
    Phase 1
    • Immuno-Oncology
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    Bispecific*

    • Azymetric™
    Preclinical
    • Oncology
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Immuno-Oncology
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    ICON2 Tissue Factor ADC

    • ZymeLink™
    Preclinical
    • Solid Tumors
    Full Details

    Bispecific

    • Azymetric™
    Preclinical
    • Infectious Disease
    Full Details

    Undisclosed

    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Dermatology
    Full Details

    Bispecific

    • Azymetric™
    • EFECT™
    Preclinical
    • Undisclosed
    Full Details

    *We entered into a collaboration with Celgene (which is now a Bristol-Myers Squibb company)